Predicting liver cirrhosis progression using precision medicine
Precision Medicine to Predict the Trajectory of Liver Cirrhosis : Prospective Cohort Study
Changi General Hospital · NCT05899309
This study looks at how different factors affect the worsening of liver cirrhosis in patients over three years to help improve their treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 21 Years to 90 Years |
| Sex | All |
| Sponsor | Changi General Hospital (other) |
| Locations | 1 site (Singapore) |
| Trial ID | NCT05899309 on ClinicalTrials.gov |
What this trial studies
This observational study aims to understand the factors influencing the progression of liver cirrhosis in patients. It will follow participants over a period of up to three years, assessing various baseline factors such as metabolic syndrome, frailty, and liver stiffness. Patients will undergo regular evaluations, including biosample collection and physical assessments, to monitor liver-related and cardiovascular outcomes. The goal is to identify predictors of decompensation in cirrhosis patients to improve management strategies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 21 to 90 years diagnosed with liver cirrhosis, regardless of its cause.
Not a fit: Patients with terminal malignancies or those unable to commit to follow-up will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better prediction and management of liver cirrhosis progression, ultimately improving patient outcomes.
How similar studies have performed: While similar studies have explored factors affecting liver cirrhosis, this specific approach focusing on precision medicine is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 21 to 90 years with the diagnosis of liver cirrhosis (regardless of etiology) * Consent to participate in the study Exclusion Criteria: * Terminal malignancy. Subjects with prognosis \< 3 months. * Patient refusal or unable to commit to study follow-up
Where this trial is running
Singapore
- Changi General Hospital — Singapore, Singapore (RECRUITING)
Study contacts
- Principal investigator: Yu Jun Wong, MD — Changi General Hospital
- Study coordinator: Siew Yoon Yap, BSc
- Email: yap.siew.yoon@singhealth.com.sg
- Phone: 68502935
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Liver Cirrhosis, Metabolic Syndrome, Spleen, Fibrosis, Frailty, liver cirrhosis, Metabolic syndrome, Cardiovascular events